Satellos Bioscience (NASDAQ:MSLE) Releases Earnings Results, Misses Expectations By $0.02 EPS

Satellos Bioscience (NASDAQ:MSLE) issued its quarterly earnings results on Friday. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.02), Zacks reports.

Satellos Bioscience Stock Performance

NASDAQ:MSLE traded down $0.16 during trading hours on Friday, reaching $7.01. The company had a trading volume of 43,311 shares, compared to its average volume of 38,248. Satellos Bioscience has a 1-year low of $4.53 and a 1-year high of $13.39. The company has a market capitalization of $146.02 million, a price-to-earnings ratio of -4.52 and a beta of 1.60. The stock has a 50 day moving average price of $7.52.

Analyst Ratings Changes

MSLE has been the topic of a number of research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Satellos Bioscience in a research note on Monday. Cantor Fitzgerald initiated coverage on Satellos Bioscience in a research note on Wednesday, March 11th. They set an “overweight” rating on the stock. Leerink Partners initiated coverage on Satellos Bioscience in a research note on Monday, April 6th. They set an “outperform” rating and a $20.00 price target on the stock. Wall Street Zen lowered Satellos Bioscience from a “sell” rating to a “strong sell” rating in a research note on Saturday, April 25th. Finally, Guggenheim began coverage on Satellos Bioscience in a research report on Tuesday, April 28th. They issued a “buy” rating and a $23.00 target price on the stock. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $18.00.

Satellos Bioscience Company Profile

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.